Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure

British Journal of Clinical Pharmacology

Volumn 44, Issue 2, 1997, Pages 183-185

  Jacqz Aigrain, Evelyne ^a   Guillonneau, Marianne ^a   Rey, Elisabeth ^b   Macher, Marie Alice ^a   Montes, Christine ^a   Chiron, Catherine ^b   Loirat, Chantal ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Enantiomers; Renal failure; Vigabatrin

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLOBAZAM; PHENOBARBITAL; PHENYTOIN; VIGABATRIN;

ADOLESCENT; AGGRESSION; AGITATION; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CONFUSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; ENANTIOMER; EPILEPSY; FATIGUE; FEMALE; GAS CHROMATOGRAPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MASS SPECTROMETRY; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; STEADY STATE; TUBEROUS SCLEROSIS; URINARY EXCRETION; VOMITING;

EID: 0030852008     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00636.x     Document Type: Article

References (19)

1. Rimmer E, Kongola G, Richens A. Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug. Br J Clin Pharmacol 1988; 25: 251-259.
2. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926.
3. Schechter PJ, Hanke NFJ, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology 1984; 34: 182-185.
4. Livingston JH, Beaumont D, Arzimanoglou A, Aicardi J. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol 1989; 27: 109S-112S.
5. Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single blind placebo controlled study. Epilepsia 1989; 30: 430-437.
6. Chiron C, Dulac O, Beaumont D, Palacias L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991; 6: S52-S59.
7. French JA, Mosier M, Wilker S, Sommerville K, Sussman N, Vigabatrin Protocol 024 Investigative Cohort. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996; 46: 54-61.
8. Hoke JF, Yuh L, Antony KK, Okerholm RA, Elberfeld JM, Sussman NM. Pharmacokinetics of vigabatrin following single and multiple oral doses in normal volunteers. J Clin Pharmacol 1993; 33: 458-462.
9. Durham SL, Hoke JF, Chen TM. Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C] vigabatrin in healthy male volunteers. Drug Metab Disp. 1993; 21: 480-484.
10. Rey E, Pons G, Richard MO, et al. Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. Br J Clin Pharmacol 1990; 30: 253-257.
11. Haegele KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986; 40: 581-586.
12. Sander JWAS, Hart YM. Vigabatrin and behaviour disturbances. Lancet 1990; 335: 57.
13. Robinson MK, Richens A, Oxley R. Vigabatrin and behaviour disturbances. Lancet 1990; ii: 504.
14. Brodie MJ, McKee PJW. Vigabatrin and psychosis. Lancet 1990; i: 1279.
15. Dam M. Vigabatrin and behaviour disturbances. Lancet 1990; i: 605.
16. Vauzelle-Kervroedan F, Pons G, Rey E, et al. Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. Fundam Clin Pharmacol 1993; 7: 585.
17. Haegele KD, Huebert ND, Ebel M, Tell GP, Schechter PJ. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988; 44: 558-565.
18. Hutcheson SJ, Yu DK, Szylleyko O, et al. Pharmacokinetics of vigabatrin in patients with varying degrees of renal function. Epilepsia 1993; 34: 106.
19. Williams K, Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985; 30: 333-354.